Update on risk-stratified management for chronic lymphocytic leukemia

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Leukemia and Lymphoma

• Publication date

  2006-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10428190600634036PMID 17064983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

  2006cited by this paper
• How I treat refractory CLL.

  2006cited by this paper
• Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies.

  2006cited by this paper
• Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.

  2006cited by this paper
• Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia.

  2006cited by this paper
• Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.

  2006cited by this paper
• Infectious complications of chronic lymphocytic leukemia.

  2006cited by this paper
• Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-Up.

  2005cited by this paper
• Salvage therapy for CLL and the role of stem cell transplantation.

  2005influential reference
• Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.

  2005cited by this paper
• ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.

  2005cited by this paper
• Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

  2005cited by this paper
• Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805

  2005cited by this paper
• Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study

  2005cited by this paper
• Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia

  2005influential reference
• Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses.

  2005influential reference
• Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q− and 17p−)

  2005cited by this paper
• Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

  2005cited by this paper
• ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype

  2005cited by this paper
• Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.

  2005cited by this paper
• Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

  2005cited by this paper
• Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

  2005cited by this paper
• Stem cell transplantation for chronic lymphocytic leukaemia

  2005cited by this paper
• Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia

  2005cited by this paper
• Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status.

  2005cited by this paper
• Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR.

  2004cited by this paper
• ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.

  2004cited by this paper
• ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

  2004cited by this paper
• VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.

  2004cited by this paper
• Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia

  2004cited by this paper
• Infections in Patients With Chronic Lymphocytic Leukemia

  2004cited by this paper
• Chronic lymphocytic leukemia with 6q− shows distinct hematological features and intermediate prognosis

  2004cited by this paper
• Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia

  2004cited by this paper
• Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) have a Markedly Increased Rate of Second Malignancy, which is the Most Common Cause of Death

  2004cited by this paper
• The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status.

  2004cited by this paper
• Vaccination Against Infections in Chronic Lymphocytic Leukemia

  2003cited by this paper
• Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope.

  2003cited by this paper
• Review Articles (434 articles)

  2003influential reference
• ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

  2003cited by this paper
• ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

  2003cited by this paper
• Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma †

  2003influential reference
• Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

  2003cited by this paper
• Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia

  2003cited by this paper
• CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells.

  2003cited by this paper
• Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

  2002cited by this paper
• Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

  2002cited by this paper
• Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.

  2002cited by this paper
• Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

  2001cited by this paper
• Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia

  2001cited by this paper
• Normal B Cells Express 51p1-Encoded Ig Heavy Chains That Are Distinct From Those Expressed by Chronic Lymphocytic Leukemia B Cells1

  2001cited by this paper
• CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia.

  2001cited by this paper
• Solid tumors after chronic lymphocytic leukemia.

  2001cited by this paper
• Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data

  2001cited by this paper
• When and how to treat chronic lymphocytic leukemia.

  2000cited by this paper
• Genomic aberrations and survival in chronic lymphocytic leukemia.

  2000influential reference
• Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

  2000cited by this paper
• Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.

  1999cited by this paper
• Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials

  1999cited by this paper
• Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

  1999cited by this paper
• Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

  1999cited by this paper
• Chlorambucil in Indolent Chronic Lymphocytic Leukemia

  1998cited by this paper
• Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.

  1998cited by this paper
• The infectious complications of chronic lymphocytic leukemia.

  1998cited by this paper
• Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

  1998cited by this paper
• Chronic lymphocytic leukemia in (Richter's) transformation.

  1998cited by this paper
• Single-agent/combination therapy of human immunodeficiency virus-related wasting.

  1998cited by this paper
• 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis.

  1997cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996influential reference
• Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis.

  1994cited by this paper
• A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

  1981cited by this paper
• Clinical staging of chronic lymphocytic leukemia.

  1977cited by this paper
• Clinical staging of chronic lymphocytic leukemia.

  1975cited by this paper

• Green Synthesis of Functionalized Gold Nanoparticles: Evaluation of Biopotential, Oxidative Stress, and Genotoxicity in Neuroglioblastoma Cells for Biomedical Applications

  2025cites this paper
• Biologically Derived Gold Nanoparticles and Their Applications

  2022cites this paper
• Different frequencies and effects of ABCB1 T3435C polymorphism on clinical and laboratory features of B cell chronic lymphocytic leukemia in Kurdish patients

  2015cites this paper
• Bryo-Synthesis of Gold Nanoparticles

  2014cites this paper
• Gold Nanoparticles in Early Detection and Treatment of Cancer : Biodistribution and Toxicities T Review

  2013cites this paper
• Molecular Diagnosis in Hematopathology

  2012cites this paper
• Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach

  2011cites this paper
• Biogenic Nanoparticles: An Introduction to What They Are, How They Are Synthesized and Their Applications

  2011cites this paper
• Molecular Diagnosis of Hematopoietic Neoplasms

  2011cites this paper
• Recurrent fevers, cough, and pulmonary opacities in a middle-aged man.

  2010cites this paper
• Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status

  2010cites this paper
• The impact of diagnosis on the therapeutic management of chronic lymphocytic leukemia

  2009influential citation
• Molecular diagnosis of hematopoietic and lymphoid neoplasms.

  2009cites this paper
• Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia

  2009cites this paper
• Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis

  2009cites this paper
• Controversies in the front-line management of chronic lymphocytic leukemia.

  2008cites this paper
• The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma

  2008cites this paper
• Stem cell transplant for chronic lymphocytic leukemia/small lymphocytic lymphoma

  2008cites this paper
• Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.

  2008cites this paper
• Biological properties of "naked" metal nanoparticles.

  2008cites this paper
• Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.

  2008cites this paper
• 2007: The year in review for Leukemia and Lymphoma

  2008cites this paper
• The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia

  2007cites this paper